TD Asset Management Inc Sells 247,634 Shares of Vertex Pharmaceuticals Incorporated $VRTX

TD Asset Management Inc decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 53.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 217,539 shares of the pharmaceutical company’s stock after selling 247,634 shares during the period. TD Asset Management Inc owned approximately 0.09% of Vertex Pharmaceuticals worth $85,197,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. Chesapeake Asset Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 110.0% in the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after acquiring an additional 33 shares during the last quarter. Access Investment Management LLC bought a new stake in Vertex Pharmaceuticals during the 2nd quarter worth approximately $27,000. Colonial Trust Co SC raised its stake in shares of Vertex Pharmaceuticals by 118.8% in the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 38 shares during the last quarter. Legacy Investment Solutions LLC purchased a new stake in shares of Vertex Pharmaceuticals in the second quarter worth approximately $29,000. Finally, Total Investment Management Inc. bought a new position in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $33,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Profile of CEO Reshma Kewalramani in TIME highlights strong leadership and continued R&D momentum, which can support investor confidence in Vertex’s long-term pipeline and strategy. Article Title
• Positive Sentiment: Market commentary noting Vertex’s relative performance vs. the Dow suggests the stock still has investor interest and can attract momentum buyers after pullbacks. Article Title
• Neutral Sentiment: General coverage in Nasdaq-100 roundup pieces points to continued attention from index investors and analysts — useful for liquidity and index-fund flows but not an immediate catalyst. Article Title
• Neutral Sentiment: Recent Q4 results (Feb 12) showed revenue growth (~9.5% y/y) but a tiny EPS miss ($5.03 vs. $5.05 consensus). Fundamentals remain strong, but the small miss tempers near-term upside until forward guidance or pipeline news arrives. (Earnings release/public filings)
• Negative Sentiment: Multiple insider sales by several senior execs on Feb 25 — including large disposals such as EVP Duncan McKechnie (4,910 shares; ~21.9% reduction) and several other EVPs/CAO — collectively amount to roughly $4.6M in disclosed sales. Clustered insider selling can trigger short-term selling pressure and signals profit-taking or personal liquidity needs rather than company weakness, but markets often interpret heavy insider sales as a negative near-term indicator. SEC Filing (example)

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 4,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $474.99, for a total value of $2,137,455.00. Following the transaction, the executive vice president owned 42,293 shares in the company, valued at approximately $20,088,752.07. This represents a 9.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Amit Sachdev sold 58,613 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $468.83, for a total value of $27,479,532.79. Following the transaction, the executive vice president directly owned 58,934 shares of the company’s stock, valued at approximately $27,630,027.22. This trade represents a 49.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 168,937 shares of company stock valued at $77,879,922. Corporate insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Weiss Ratings upgraded Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, February 4th. Leerink Partners lifted their price objective on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a report on Monday, December 29th. Wolfe Research upgraded shares of Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 target price for the company in a research note on Tuesday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $590.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Finally, Sanford C. Bernstein reissued an “outperform” rating and set a $577.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Twenty-two research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $542.00.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $480.13 on Friday. The firm has a market cap of $121.97 billion, a PE ratio of 31.32 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.68. The stock has a fifty day moving average price of $465.74 and a 200-day moving average price of $431.13.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The company had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.18 billion. During the same period last year, the firm posted $3.98 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 9.5% compared to the same quarter last year. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.